Company Filing History:
Years Active: 2024
Title: Samy Omri: Innovator in Cyclic Peptides
Introduction
Samy Omri is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of cyclic peptides, particularly through his innovative research and patent work. His expertise lies in the development of novel cyclic peptide GHRP-6 analogs, which have potential therapeutic applications.
Latest Patents
Samy Omri holds a patent for cyclic peptides and their uses, specifically focusing on novel cyclic peptide GHRP-6 analogs. These analogs are described by the formula (I) or pharmaceutically acceptable esters or salts thereof. The cyclic peptide GHRP-6 analogs may be utilized for modulating CD36 activity, which is crucial for treating CD36-related diseases, disorders, or conditions in subjects. Notable conditions include atherosclerosis and age-related macular degeneration.
Career Highlights
Samy Omri is affiliated with the Université de Montréal, where he conducts his research and development work. His career is marked by a commitment to advancing the understanding and application of cyclic peptides in medical science. His innovative approach has led to the creation of valuable intellectual property in the form of patents.
Collaborations
Samy Omri collaborates with esteemed colleagues such as William D. Lubell and Huy Ong. These partnerships enhance the research efforts and contribute to the advancement of knowledge in the field of cyclic peptides.
Conclusion
Samy Omri's work in cyclic peptides represents a significant advancement in medical research, particularly in the treatment of diseases related to CD36 activity. His contributions through patents and collaborations highlight his role as an influential inventor in the scientific community.